Mabion biotech signs deal with US' Novavax on COVID-19 vaccine technology transfer
Listed biotech firm Mabion signed a deal with US pharma company Novavax to transfer the manufacturing process and open the way for commercial-scale production of an antigen for a COVID-19 vaccine candidate, Mabion said in a market filing.
The Master Service Agreement enables Mabion "with assistance of Novavax, to initiate activities required to transfer the manufacturing process and to establish the feasibility of commercial-scale manufacturing of antigen for Novavax's vaccine candidate" at Mabion's premises, the filing read. Mabion expects that the transfer of the technology and its verification will be completed in H1'2021.
The deal is effective through December 31, 2023.
Mabion and Novavax intend, should their cooperation continue, "to include [Mabion's] plant as part of the supply chain for commercial production of the adjuvanted protein-based vaccine candidate," Mabion said.
Mabion could get up to PLN 40 mln for the project from state development fund PFR in the form of debt and capital investment, Mabion said in a separate filing. Specifically, PFR could provide up to PLN 30 mln in a 3Y loan or bond issue and buy Mabion shares from a new share issue for up to PLN 10 mln.
